{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:12:35Z","timestamp":1789229555157,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T00:00:00Z","timestamp":1485216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1038\/pcan.2016.71","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T07:00:16Z","timestamp":1485241216000},"page":"221-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL"],"prefix":"10.1038","volume":"20","author":[{"given":"A H","family":"Bryce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Alumkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-1754","authenticated-orcid":false,"given":"A","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C S","family":"Higano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C N","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Rathkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-595X","authenticated-orcid":false,"given":"J","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Abhyankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Krivoshik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Phung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T M","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,24]]},"reference":[{"key":"BFpcan201671_CR1","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","volume":"19","author":"AM Aparicio","year":"2013","unstructured":"Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013; 19: 3621\u20133630.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201671_CR2","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","volume":"20","author":"H Beltran","year":"2014","unstructured":"Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 2014; 20: 2846\u20132850.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201671_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1200\/JCO.2011.39.1300","volume":"30","author":"PS Nelson","year":"2012","unstructured":"Nelson PS . Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol 2012; 30: 644\u2013646.","journal-title":"J Clin Oncol"},{"key":"BFpcan201671_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015; 520: 353\u2013357.","journal-title":"Nature"},{"key":"BFpcan201671_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424\u2013433.","journal-title":"N Engl J Med"},{"key":"BFpcan201671_CR6","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148\u20131159.","journal-title":"J Clin Oncol"},{"key":"BFpcan201671_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205\u2013216.","journal-title":"J Natl Cancer Inst"},{"key":"BFpcan201671_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228\u2013247.","journal-title":"Eur J Cancer"},{"key":"BFpcan201671_CR9","doi-asserted-by":"crossref","unstructured":"Morris MJ, Loriot Y, Beer TM, Higano CS, Armstrong AJ, Sternberg CN et al. Sensitivity analyses for radiographic progression-free survival (rPFS): results from the phase 3 PREVAIL trial comparing enzalutamide to placebo [abstract 5054]. J Clin Oncol 2014; 32.","DOI":"10.1200\/jco.2014.32.15_suppl.5054"},{"key":"BFpcan201671_CR10","doi-asserted-by":"publisher","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","volume":"13","author":"AJ Armstrong","year":"2007","unstructured":"Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M . A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396\u20136403.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201671_CR11","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","volume":"21","author":"S Halabi","year":"2003","unstructured":"Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232\u20131237.","journal-title":"J Clin Oncol"},{"key":"BFpcan201671_CR12","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1200\/JCO.2002.11.021","volume":"20","author":"O Smaletz","year":"2002","unstructured":"Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972\u20133982.","journal-title":"J Clin Oncol"},{"key":"BFpcan201671_CR13","doi-asserted-by":"crossref","unstructured":"Beer TM, Armstrong AJ, Sternberg CN, Higano CS, Rathkopf DE, Loriot Y et al. Enzalutamide (ENZA) in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): final analysis of the phase 3 PREVAIL study [abstract 5036]. J Clin Oncol 2015; 33.","DOI":"10.1200\/jco.2015.33.15_suppl.5036"},{"key":"BFpcan201671_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 2016; 22: 298\u2013305.","journal-title":"Nat Med"},{"key":"BFpcan201671_CR15","doi-asserted-by":"crossref","unstructured":"Small EJ, Huang J, Youngren J, Sokolov A, Aggarwal RR, Thomas GV et al. Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): preliminary results from the SU2C\/PCF\/AACR West Coast Prostate Cancer Dream Team (WCDT) [abstract 5003]. J Clin Oncol 2015; 33.","DOI":"10.1200\/jco.2015.33.15_suppl.5003"},{"key":"BFpcan201671_CR16","doi-asserted-by":"crossref","unstructured":"Small EJ, Aggarwal RR, Huang J, Sokolov A, Zhang L, Alumkal JJ et al. Clinical and genomic characterization of metastatic small cell\/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): results from the SU2C\/PCF\/AACRWest Coast Prostate Cancer Dream Team (WCDT) [abstract 5019]. Presented at the 2016 American Society of Clinical Oncology Annual Meeting; 3\u20137 June, 2016: Chicago, IL, USA.","DOI":"10.1200\/JCO.2016.34.15_suppl.5019"},{"key":"BFpcan201671_CR17","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","volume":"50","author":"JM Fitzpatrick","year":"2014","unstructured":"Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 2014; 50: 1617\u20131627.","journal-title":"Eur J Cancer"},{"key":"BFpcan201671_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163\u20131177.","journal-title":"Lancet"},{"key":"BFpcan201671_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737\u2013746.","journal-title":"N Engl J Med"},{"key":"BFpcan201671_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale CL, Burdett S, Rydzewska LH, Albiges L, Clarke NW, Fisher D et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 2016; 17: 243\u2013256.","journal-title":"Lancet Oncol"},{"key":"BFpcan201671_CR21","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"P Hoskin","year":"2014","unstructured":"Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014; 15: 1397\u20131406.","journal-title":"Lancet Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/pcan201671.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/pcan201671","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/pcan.2016.71","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/pcan201671.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T01:03:20Z","timestamp":1684458200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,24]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["BFpcan201671"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2016.71","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,24]]},"assertion":[{"value":"14 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AHB has nothing to disclose. JJA\u2019s institution has received research funding from Aragon Pharmaceuticals, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, ImClone Systems, Millennium and Novartis. JJA has received income for consulting with Astellas Pharma and for educational sessions with Bayer HealthCare Pharmaceuticals. AA is an advisor for Astellas, Bayer, Dendreon, Janssen, Medivation and Sanofi; he has received honoraria from Dendreon and Sanofi; he is on a speakers bureau for Dendreon; his institution has received research funding from Active Biotech, Astellas, Bayer, Dendreon, Janssen, Medivation, Novartis, Pfizer and Sanofi; he has received travel expenses from Dendreon, Janssen and Medivation; and he has a patent pending that involves his institution and Janssen for technology relating to oncology. CSH is an advisor for AbbVie, Bayer, BHR Pharma, Dendreon, Emergent BioSolutions, Ferring, Genentech, Medivation, Orion Corporation, Pfizer and Sanofi; her institution has received research funding from Algeta\/Bayer, Aragon Pharmaceuticals, AstraZeneca, Dendreon, Emergent BioSolutions, Exelixis, Genentech, Medivation, Millennium, OncoGenex, Sanofi and Teva; and she has received travel expenses from AbbVie, Amgen, Astellas Pharma, Bayer, Dendreon, Emergent BioSolutions, Ferring, Genentech, Johnson & Johnson, Medivation, Ockham, Orion Pharma, Pfizer, Sanofi and Teva. PI is an advisor for Astellas, Ferring, Janssen and Medivation, and has received research funding from Astellas, Bavarian Nordic and Medivation. CNS has received institutional research funding or honoraria from Astellas, Bayer, Cougar Biotechnology (now Janssen Oncology), Medivation and Sanofi. DR has received research funding from Celgene, Ferring, Janssen, Medivation, Millenium and Novartis. YL is an advisor for Astellas, Bristol-Myers Squibb, Ipsen, Janssen, Roche and Sanofi; his institution has received research funding from Sanofi; and he has received travel expenses from Astellas, Bristol-Myers Squibb and Sanofi. JD has received honoraria from, is an advisor for, and is on a speakers bureau for Astellas. BT has received research funding from Astellas, Ferring and Sanofi, and honoraria from Astellas, Bayer, Ferring, Medivation and Sanofi. SA was an employee of Medivation at the time of study conduct. PL is an employee of Medivation. AK is an employee of Astellas. DP is an employee of Astellas. TMB has stock and other ownership interests in Salarius Pharmaceuticals; he is an advisor for Astellas, AstraZeneca, Bayer, Churchill Pharmaceuticals, Dendreon, Janssen Japan, Novartis and F Hoffmann-La Roche; and his institution has received research funding from Astellas, Bristol-Myers Squibb, Dendreon, Janssen Research & Development, Medivation, OncoGenex and Sotio.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}